Though exact dosing for retatrutide in the weight-loss setting is still being defined (because many of the uses remain investigational), in the key trial adults with obesity treated weekly showed large body weight reductions: e.g., up to ~17.5% at 24 weeks and up to ~24% at 48 weeks in certain dose groups
healthcare ecosystems of this database limits generalizability to global populations, and missing data elements complicate accurate benefit-risk assessments
Results Among 97,255 patients from 55 centers, 67.4% agreed to be contacted for future research
Common side effects The most common side effects of Contrave include nausea, constipation, headache, dizziness, trouble sleeping, anxiety, shaking, and dry mouth
Marre, M., Shaw, J., Brndle, M., Bebakar, W